Study Finds No Link Between BNT162b2 COVID-19 Vaccine and Facial Nerve Palsy
Study investigators assessed whether the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is associated with greater risk of peripheral facial nerve palsy.
Study investigators assessed whether the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is associated with greater risk of peripheral facial nerve palsy.
The approval is indicated for individuals 16 years of age and older, however the vaccine remains available to those aged 12 years and older under the EUA.
The early COVID-19 vaccination campaign in the United States resulted in almost 140,000 averted COVID-19 deaths as of May 9, 2021.
The American College of Obstetricians and Gynecologists (ACOG) strongly recommends that all eligible individuals, including those who are pregnant, recently pregnant, and lactating, receive a COVID-19 vaccine.
Currently available vaccines are effective for preventing SARS-CoV-2 infection and COVID-19-associated hospitalization.
Following implementation of COVID-19 restrictions in Australia in April 2020, there was a reduction in antibiotic dispensing.
After concluding that a third dose of a COVID-19 vaccine is needed to fight off waning immunity in the fully vaccinated.
COVID-19 vaccines are well tolerated among individuals who are pregnant, lactating, or planning pregnancy.
The Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines are highly effective for preventing COVID-19-associated hospitalization among older adults in the US.
The U.S. FDA on Thursday authorized a third “booster” shot of coronavirus vaccines for people with weakened immune systems.